The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 18, 2025

Filed:

May. 11, 2018
Applicants:

The General Hospital Corporation, Boston, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Inventors:

Moshe Sade-Feldman, Boston, MA (US);

Keren Yizhak, Cambridge, MA (US);

Gad Getz, Boston, MA (US);

Nir Hacohen, Boston, MA (US);

Assignees:

The General Hospital Corporation, Boston, MA (US);

The Broad Institute, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/45 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 38/45 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/46449 (2023.05); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 15/10 (2013.01); C12Q 1/6886 (2013.01); A61K 2239/57 (2023.05); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01);
Abstract

The subject matter disclosed herein is generally directed to CD8+ tumor infiltrating lymphocytes comprising gene signatures associated with response to immunotherapy treatment. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the gene signatures. Specifically, disclosed herein are gene signatures associated with response to checkpoint blockade therapy and immune cell subtypes characterized by said gene signatures. Further disclosed are methods of using said gene signatures and immune cell subtypes. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs enriched for a specific subtype.


Find Patent Forward Citations

Loading…